Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesbiOasis Technologies Inc

biOasis Technologies Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.005 CAD 0.00(0%)
Last update at 2024-12-24T14:30:00Z
Market Cap
0.40M

Momentum Score

…

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
1.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.27M
Revenue Per Share
0.00
Gross Profit TTM
-1.19M
Debt / Equity
-
ROE
-
Net Debt
0.17M
ROCE
676.27%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Income before tax - -2.96M 0.70M -4.06M -3.47M
Net income - -2.96M 0.70M -4.06M -3.47M
Selling general administrative - 2.41M 2.46M 3.17M 4.31M
Gross profit - -0.02M 4.08M 0.61M 1.41M
Reconciled depreciation - 0.05M 0.06M 0.07M 0.07M
Ebit - -4.89M -0.09M -5.20M -6.23M
Ebitda - -4.83M -0.02M -5.12M -6.17M
Depreciation and amortization 0.05M 0.06M 0.07M 0.07M 0.06M
Operating income - -4.89M -0.08M -5.19M -6.24M
Other operating expenses - 3.63M 3.70M 5.21M 6.28M
Interest expense - 0.65M 0.04M 0.05M 0.00M
Interest income - - - - 0.00M
Net interest income - -0.65M -0.04M -0.05M 0.00M
Income tax expense - -0.64M -0.32M -0.55M -1.38M
Total revenue - 0.04M 4.08M 0.61M 1.42M
Total operating expenses - 3.63M 3.70M 5.21M 6.27M
Cost of revenue - 0.05M - 0.00M 0.01M
Total other income expense net - 1.29M 0.46M 0.59M 1.38M
Net income from continuing ops - -2.96M 0.70M -4.06M -3.47M
Net income applicable to common shares - -2.96M 0.70M -4.06M -3.47M
Breakdown 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Type yearly yearly yearly yearly yearly
Date 2022-02-28 2021-02-28 2020-02-29 2019-02-28 2018-02-28
Total assets 2.27M 3.28M 0.94M 1.74M 1.22M
Intangible assets 0.16M 0.21M 0.27M 0.33M 0.39M
Total liab 4.18M 2.87M 3.43M 2.29M 0.79M
Total stockholder equity -1.92M 0.41M -2.49M -0.55M 0.43M
Other current liab - - - 0.26M -
Common stock 27.45M 27.26M 25.42M 24.20M 22.79M
Capital stock 27.45M 27.26M 25.42M 24.20M -
Retained earnings -40.65M -37.69M -38.39M -34.34M -30.86M
Other liab 0.79M 0.91M 0.43M 1.03M -
Cash 1.73M 2.74M 0.58M 1.36M 0.68M
Total current liabilities 2.99M 1.90M 2.48M 1.26M 0.79M
Net debt 0.17M - 0.43M - -
Short long term debt 1.50M 0.06M 0.49M - -
Other stockholder equity 0.18M 0.19M 0.02M 0.03M 0.03M
Property plant equipment 0.00M 0.00M 0.02M 0.03M 0.04M
Total current assets 2.11M 3.06M 0.65M 1.38M 0.79M
Net tangible assets -2.08M 0.19M -2.76M -0.87M 0.05M
Net receivables 0.10M 0.03M 0.01M 0.01M 0.03M
Long term debt 0.40M 0.06M 0.52M - -
Accounts payable 1.49M 1.84M 1.99M 1.00M 0.79M
Non currrent assets other - - - 0.36M 0.43M
Non current assets total 0.16M 0.22M 0.29M 0.36M 0.43M
Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Investments - 0.00M 0.01M 0.00M 0.39M
Change to liabilities - -0.51M 0.01M 0.74M 0.48M
Total cashflows from investing activities - - 0.01M 0.01M 0.39M
Net borrowings - 2.53M -0.58M 1.29M 1.29M
Total cash from financing activities - 2.64M 0.31M 2.49M 3.53M
Change to operating activities - 0.18M -0.24M -0.05M 0.07M
Net income - -2.96M 0.70M -4.06M -3.47M
Change in cash - -1.01M 2.16M -0.78M 0.68M
Begin period cash flow 1.73M 2.74M 0.58M 1.36M 0.68M
End period cash flow 1.73M 1.73M 2.74M 0.58M 1.36M
Total cash from operating activities - -3.64M 1.77M -3.30M -3.23M
Issuance of capital stock - 0.20M 0.19M 1.21M 3.53M
Depreciation - 0.05M 0.06M 0.07M 0.07M
Change to inventory - 0.51M -0.01M -1.01M -0.23M
Change to account receivables - -0.07M -0.02M -0.00M 0.02M
Other cashflows from financing activities - 2.81M 0.82M 2.58M 0.39M
Change to netincome - -0.98M 1.15M -0.06M -0.40M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - -0.40M -0.25M 0.69M 0.57M
Stock based compensation - 0.44M 0.28M 0.57M 0.98M
Other non cash items - 0.65M 0.11M 0.05M -1.38M
Free cash flow - -3.64M 1.77M -3.30M -3.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BTI
biOasis Technologies Inc		 -
-%		 0.01 - - 1.47 54.04 9.11 -0.78
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.04%		 0.47 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -0.01
9.09%		 0.05 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

biOasis Technologies Inc

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

157 Church Street, New Haven, CT, United States, 06510

203 533 7082

https://www.bioasis.us

Name Title Year Born
Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. Exec. Chairman, CEO & Pres 1958
Mr. Dave Jenkins Chief Financial Officer NA
Mr. Graeme Dick Director of Investor Relations NA
Mr. Kim Elton Director of Marketing NA
Mr. Doug Williams MBA Exec. VP & Chief Bus. Officer NA
Dr. Mei Mei Tian VP & Head of External Research NA
Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. Executive Chairman, CEO & President 1958
Mr. David P. Jenkins Chief Financial Officer 1962
Mr. Aaron Elton Director of Marketing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…